Quest for a Treatment for Alzheimer’s disease: Mission Impossible? Perhaps not!
Dr. Jack Jhamandas is currently a Distinguished University Professor in the Division of Neurology, Department of Medicine at the University of Alberta. He received his BSc in Applied Physics and MSc in Biophysics from the University of Alberta, his MD from the University of Calgary and PhD in Neuroscience from McGill University. He completed his clinical training in Internal Medicine at the Toronto Western Hospital and in Neurology at the Montreal Neurological Institute. Dr. Jhamandas is a neurologist and neuroscientist whose research program on Alzheimer's disease has been funded by the CIHR and other agencies.
He has received the Gold Medal in Medicine from the Royal College of Physicians and Surgeons of Canada; a Killam Professorship; a Tier 1 Canada Research Chair in Alzheimer's Research and elected a Fellow of the Canadian Academy of Health Sciences. He has published over 100 peer reviewed manuscripts and holds several patents.
The development of novel and effective disease modifying therapies for Alzheimer’s disease is one of the greatest scientific challenges of our time. Over the past 25 years, Dr. Jhamandas’ experimental studies that have advanced knowledge in this area and hold the promise of yielding novel therapeutics for the disease. He is President and CEO of Egeiro Pharmaceuticals Inc. that he co-founded with Dr. Lorne Tyrrell and Sir Michael Houghton.
Summary of Presentation:
The development of novel and effective disease modifying therapies for Alzheimer’s disease is one of the greatest scientific challenges of our time. In this talk Dr. Jhamandas will cover experimental studies that have advanced knowledge in this area and hold the promise of yielding transformative therapy for Alzheimer’s disease. A more detailed account of Dr. Jhamandas and his team’s research efforts is profiled in the issue of the Edify Magazine (May/June, 2025 issue).
https://edifyedmonton.com/urban/innovation-technology/distant-memory/